Liver damage is a well-recognised complication of gene therapies based on adeno-associated virus (AAV) vectors, and other ...

Astellas is to work with UK biotech Adaptimmune Therapeutics to develop allogeneic ‘off-the-shelf’ T-cell therapies for cancer ... universal donor cell and gene editing technology it obtained ...

The appointment of a new CEO by Astellas Pharma—Japan’s fourth largest pharma company—is unlikely to slow down its development of gene therapies—efforts boosted by the recent lifting of a ...

Shares of Taysha Gene Therapies (NASDAQ ... involved in the gene therapy field, after the Astellas collaboration news I chose to reenter the stock ahead of 1H 23 Rett data updates.

Cancer is well represented in the Astellas Pharma portfolio and pipeline, but the drugmaker has made diversification a key part of its growth strategy. Newer products in its drug lineup include a ...

Astellas Gene Therapies is turning out the lights at a California production plant. In a move expected to impact around 100 employees, Astellas Gene Therapies is closing its Eccles ...

JMP Securities Silvan Tuerkcan revised the firm’s view on Taysha Gene Therapies, Inc. (NASDAQ:TSHA), raising the price target ...

Astellas’s gene therapy division formed from the 2020 acquisition of Audentes Therapeutics, which brought a pipeline of gene therapies in various stages of development for rare inherited disorders.

No identified affiliates for Astellas Gene Therapies in the 2024 election cycle. Contributions to 527s are not included in the Individuals, PACs, Soft (Indivs), or Soft (Orgs) columns, so the sum of ...

In light of this, Astellas, a global pharmaceutical company based in Tokyo, Japan, has set a long-term goal of advancing cell and gene therapies for treating eye diseases. Degenerative eye ...

- Agreement grants Astellas rights to employ Sangamo's novel proprietary capsid, STAC-BBB, for up to five potential neurological disease targets - ...

Cell and gene therapies are also a key part of Astellas’s growth strategy, building off of its 2020 acquisition of gene therapy developer Audentes Therapeutics. Within gene therapy, the Tokyo ...